Catalog No.	C045P.05
Product Name	Efalizumab Biosimilar, Endotoxin 0.05 EU/mg | C045P.05
Supplier Name	Syd Labs, Inc.
Brand Name	Syd Labs
Synonyms	Integrin, alpha L, antigen CD11A, p180, lymphocyte function-associated antigen 1, alpha polypeptide, ITGAL, LFA-1, LFA1A, integrin subunit alpha L
Summary	Recombinant Humanized IgG1 Monoclonal Antibody.
Isotype	Human IgG1 kappa.
Source/Host	The anti-human CD11a monoclonal antibody efalizumab biosimilar was produced in mammalian cells.
Specificity/Sensitivity	The in vivo grade efalizumab biosimilar specifically binds to the human CD11a.
Applications	ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by efalizumab.
Form Of Antibody	0.2 uM filtered solution, pH 6.0, no stabilizers or preservatives.
Endotoxin	< 0.05 EU per 1 mg of the protein by the LAL method.
Purity	>95% by SDS-PAGE under reducing conditions and HPLC.
Shipping	The Efalizumab Biosimilar, Endotoxin 0.05 EU/mg is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.
Note	The research grade Efalizumab biosimilar protein is for research use only (RUO). Recombinant human IgG1 isotype controls are available. Condition of sample preparation and optimal sample dilution should be determined experimentally by the investigator.
Order Offline	Phone: 1-617-401-8149 Fax: 1-617-606-5022 Email: message@sydlabs.com Orleave a message with a formal purchase order (PO) Or credit card.

Description

C045P.05: Efalizumab Biosimilar, Endotoxin 0.05 EU/mg

Recombinant Humanized IgG1 Monoclonal Antibody.

Background

Efalizumab Biosimilar uses the same protein sequences as the therapeutic antibody efalizumab.

Efalizumab is a monoclonal anti-CD11a antibody used to treat moderate to severe plaque psoriasis.

Humanized IgG1 kappa isotype monoclonal antibody that binds to human CD11a. Efalizumab has a molecular weight of approximately 150 kilodaltons and is produced in a Chinese hamster ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin.

Efalizumab binds to CD11a, a subunit of leukocyte function antigen-1 (LFA-1), which is expressed on all leukocytes. As a result efalizumab decreases cell surface expression of CD11a.

Efalizumab Biosimilar from: Efalizumab Biosimilar, Endotoxin 0.05 EU/mg: C045P.05 Syd Labs

No more offers for this product!